232 related articles for article (PubMed ID: 11521714)
1. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
2. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H; Gown AM
Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
[No Abstract] [Full Text] [Related]
3. Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe.
Piccart MJ
Ann Oncol; 2001; 12 Suppl 1():S89-94. PubMed ID: 11521728
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of HER2 in breast cancer.
Piccart M; Lohrisch C; Di Leo A; Larsimont D
Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
7. HER2 testing and correlation with efficacy of trastuzumab therapy.
Fornier M; Risio M; Van Poznak C; Seidman A
Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
[TBL] [Abstract][Full Text] [Related]
8. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
9. [Human epidermal growth factor receptor 2 testing in breast cancer].
Ivković-Kapicl T; Knezević-Usaj S
Med Pregl; 2010; 63(1-2):69-74. PubMed ID: 20873313
[TBL] [Abstract][Full Text] [Related]
10. [HER2 testing in breast cancer].
Yoshimura K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
[No Abstract] [Full Text] [Related]
11. HER2 testing recommendations in Australia.
Bilous M;
Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
14. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
15. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
17. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Paik S; Bryant J; Tan-Chiu E; Romond E; Hiller W; Park K; Brown A; Yothers G; Anderson S; Smith R; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2002 Jun; 94(11):852-4. PubMed ID: 12048273
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
Sawaki M; Ito Y; Tada K; Mizunuma N; Takahashi S; Horikoshi N; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
Tumori; 2004; 90(1):40-3. PubMed ID: 15143970
[TBL] [Abstract][Full Text] [Related]
20. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]